Elkayal Hassan E, Sagoo Mandeep S, Negretti Guy S
Ocular Oncology Service, Moorfields Eye Hospital, London, United Kingdom.
Department of Ophthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt ; and.
Retina. 2025 Mar 1;45(3):501-508. doi: 10.1097/IAE.0000000000004323. Epub 2025 Feb 17.
To investigate the use of intravitreal bevacizumab for the treatment of subretinal fluid (SRF) and intraretinal fluid associated with circumscribed choroidal hemangiomas.
This was a retrospective review of all patients treated with at least three bevacizumab injections for circumscribed choroidal hemangiomas-associated SRF between May 2020 and August 2023 in Moorfields eye hospital. Outcome measures included change in best-corrected visual acuity, change in patient-reported symptoms, change in SRF, and change in central subfield thickness. Data on further management after cessation of injections were analyzed.
The study included nine patients. Median best-corrected visual acuity was 6/19 before and 6/24 after injections ( P = 0.41). Central subfield thickness decreased from a median of 466 to 447 µ m ( P = 0.11). Two thirds of (n = 6) patients did not show any reduction in foveal SRF, one third (n = 3) showed a partial reduction, and no patients had a complete resolution of SRF. Eight patients received rescue-photodynamic therapy, and one received external beam radiotherapy. Best-corrected visual acuity changed from a median of 6/60 to a median of 6/12 after rescue treatment ( P = 0.63). The median central subfield thickness decreased significantly from 470 µ m to 249 µ m ( P = 0.01).
Intravitreal bevacizumab is unlikely to be an effective treatment for exudative circumscribed choroidal hemangiomas.
探讨玻璃体内注射贝伐单抗治疗局限性脉络膜血管瘤相关的视网膜下液（SRF）和视网膜内液的疗效。
这是一项对2020年5月至2023年8月在摩尔菲尔德眼科医院接受至少三次贝伐单抗注射治疗局限性脉络膜血管瘤相关SRF的所有患者的回顾性研究。观察指标包括最佳矫正视力的变化、患者报告症状的变化、SRF的变化以及中央子野厚度的变化。分析了注射停止后进一步治疗的数据。
该研究纳入了9名患者。注射前最佳矫正视力中位数为6/19，注射后为6/24（P = 0.41）。中央子野厚度从中位数466μm降至447μm（P = 0.11）。三分之二（n = 6）的患者黄斑区SRF未减少，三分之一（n = 3）的患者部分减少，没有患者SRF完全消退。8名患者接受了挽救性光动力疗法，1名患者接受了外照射放疗。挽救治疗后最佳矫正视力中位数从6/60变为6/12（P = 0.63）。中央子野厚度中位数从470μm显著降至249μm（P = 0.01）。
玻璃体内注射贝伐单抗不太可能是渗出性局限性脉络膜血管瘤的有效治疗方法。
